May 29 - 30, 2020

ASCP
2020 Annual Meeting

Virtual Conference

www.ascpmeeting.org
Dear Colleagues,

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am pleased to welcome you to our inaugural Virtual Annual Meeting. While we cannot gather in the traditional way this year, we are excited to offer a virtual option that will bridge the gap until we can meet again in person. I want to thank you for staying with us during these unprecedented times.

We all continue to face the impact of the global novel coronavirus pandemic while working in new and novel ways dealing with issues of social distancing and isolation, food scarcity and economic insecurity. It is our goal to present state of the art information that will enable you to navigate these unchartered waters while providing high levels of care with confidence.

The ASCP is committed to finding and testing new therapies for our patients. We want to advance not only the field of psychopharmacology but treatment research in general. Many advances first presented at our annual meeting over the years have become mainstays not only in our treatment of serious mental disorders but in the way we design and conduct our clinical trials. I am sure that we will see presentations and posters during this meeting that will become important methods for caring for our patients in the future.

While our program might be condensed this year, we are happy to present many of the most anticipated and highly regarded sessions of past Annual Meetings, such as, Federal Agency Updates, Clinical Updates in Psychopharmacology, Pharmaceutical Pipelines and virtual poster sessions. The meeting will also offer a timely and informative session on caring for patients during the novel coronavirus (COVID-19) pandemic. On a final note, I would like to take this opportunity to thank the ASCP Officers, the Steering Committee led by Susan Kornstein, M.D., and Mark Rapaport, M.D., and the Program Committee led by Erika Saunders, M.D., and Lee Cohen, M.D., not only for their dedication to planning the 2020 Annual Meeting but adapting the program to a virtual format in a matter of a few short weeks and ensuring we continue to advance the science and practice of clinical psychopharmacology in new and meaningful ways. At the conclusion of the meeting, please join several ASCP Board of Directors for virtual conversation hours and the opportunity to meet respected leaders in the field.

Once again, on behalf of the ASCP Board of Directors, thank you for joining us today. I hope you enjoy the meeting.

Sincerely,

Madhukar Trivedi, M.D.
ASCP President
Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2020 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

- **2020 Program Highlights**
  - **Friday, May 29**
    - Federal Agency Updates Plenary
    - Poster Session I
  - **Saturday, May 30**
    - Clinical Updates in Psychopharmacology
    - Poster Session II
    - Pharma Pipeline: 10 presentations of Phase 1 and Phase 2 developments
  - **Enduring Material**
    - 2020 ASCP Psychopharmacology Update: State-of-the-Art Spring Meeting recorded lectures.
  - **Clinical Track** – Sessions focused on topics of immediate clinical relevance

- **Organization**
  - The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
  - The Steering Committee organizes the meeting.
  - The Program Committee evaluates submitted proposals and develops program innovations.
  - Federal agency collaborations:
    - NIAAA – National Institute on Alcohol Abuse and Alcoholism
    - NIDA – National Institute of Drug Abuse
    - NIMH – National Institute of Mental Health
    - PCORI – Patient-Centered Outcomes Research Institute
    - SAMHSA – Substance Abuse and Mental Health Services Administration
  - Society collaborations:
    - American Foundation for Suicide Prevention (AFSP)
  - Parthenon Management Group organizes the ASCP Annual Meeting.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,

Susan G. Kornstein, M.D.  
Steering Committee Co-chair

Mark Rapaport, M.D.  
Steering Committee Co-chair

Erika Saunders, M.D.  
Program Committee Co-chair

Lee Cohen, M.D.  
Program Committee Co-chair
COVID-19 TALK
Friday, May 29th from 8:30 a.m. – 9:30 a.m.

Jay Shore, M.D.
University of Colorado Anschutz Medical Campus

Jay H. Shore received his medical and public health degrees from Tulane University. He is a Professor at the Department of Psychiatry and Family Medicine, School of Medicine And Centers for American Indian and Alaska Native Health, Colorado School of Public Health. Dr. Shore is Director of Telemedicine Programming for Department of Psychiatry, School of Medicine and Director of Telemedicine for the Helen and Arthur E. Johnson Depression Center University of Colorado Anschutz Medical Campus, as well as Chief Medical Officer of AccessCare a provider of telemental health services of rural and under served populations. He has served in leadership positions for the American Telemedicine Association and current Chair of the American Psychiatric Association Telepsychiatry Committee.
Federal Agency Updates Plenary
Friday, May 29th from 9:45 a.m. – 12:15 p.m.

Sarah Lisanby, M.D.
National Institute of Mental Health (NIMH)

Sarah Hollingsworth “Holly” Lisanby, MD, is an experienced translational researcher, senior leader, and innovator of neuromodulation technologies to study and treat psychiatric disorders. Dr. Lisanby is Director of the Division of Translational Research at NIMH, which funds research supporting the discovery of preventions, treatments, and cures for mental illness across the lifespan. She is the Founder and Director of the Noninvasive Neuromodulation Unit in the NIMH Intramural Research Program, a productive translational research program specializing in the use of brain stimulation tools to measure and modulate neuroplasticity to improve mental health. Dr. Lisanby is former Chair of the Duke University Department of Psychiatry & Behavioral Sciences, and JP Gibbons Endowed Professor at Duke University. She founded and directed both the Duke University and the Columbia University Divisions of Brain Stimulation, where she built interdisciplinary research programs specializing in the convergence of Psychiatry, Neuroscience and Engineering. She co-led and currently serves on the NIH BRAIN Initiative Team focused on large-scale neural recording and modulation devices.

Dr. Lisanby has been principal investigator on a series of NIH and DARPA funded studies on the development of novel neuromodulation technologies, including studies on the rational design of magnetic and electrical seizure therapies. Her team pioneered magnetic seizure therapy (MST) as a novel depression treatment from the stages of animal testing, first-in-human, and now international clinical trials. She led a series of studies involving transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), MST, vagus nerve stimulation (VNS), deep brain stimulation (DBS) and other devices. Dr. Lisanby published a series of studies that established the paradigm of fMRI-guided TMS during working memory training to improve working memory performance in healthy volunteers, and to remediate working memory deficits following sleep deprivation. This paradigm has been extended to mitigate the effects of age-related decline in working memory.

A prolific author with over 280 scientific publications, she has received national and international recognition, including a Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD), the Max Hamilton Memorial Prize of the Collegium Internationale Neuro-Psychopharmacologicum (CINP), the Gerald Klerman Award from the National Depression and Manic Depression Association (NMDA), and the Eva King Killam Research Award from the American College of Neuropsychopharmacology (ACNP). She has been a member of the NIMH Board of Scientific Counselors, and has chaired or been a member of a variety of NIH Study Sections. Dr. Lisanby served on the FDA Neurological Devices Advisory Panel, is on five editorial boards, and has held key leadership positions with numerous professional associations, including serving as President for the Association for Convulsive Therapy/International Society of Neurostimulation, and the International Society for Transcranial Stimulation, and Chair of the American Psychiatric Association Task Force to Revise the Practice on Electroconvulsive Therapy (ECT).
Federal Agency Updates Plenary  
Friday, May 29th from 9:45 a.m. – 12:15 p.m.

George Koob, Ph.D.  
National Institute on Alcohol Abuse & Alcoholism (NIAAA)

George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as of January 27, 2014. He is also a Senior Investigator at the Intramural Research Program of the National Institute on Drug Abuse where he directs the Neurobiology of Addiction Laboratory in the Integrative Neurosciences Research Branch. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 700 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field, and a textbook for upper division undergraduates and graduate students called “Drugs, Addiction and the Brain.” He has mentored 11 Ph. D students and over 80 post-doctoral fellows and mentored or co-mentored 11 K99’s. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972. He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine (USA) and award of the Legion of Honor (France).
Dr. Gandotra serves as the Chief Medical Officer for SAMHSA. Previously, Dr. Gandotra served as the Chief Medical Officer for a large nationwide addiction treatment network where he has developed national strategies specifically aimed at reducing risk and improving outcomes. He is familiar with the development and utilization of medical services budgets, nuances of regulations, and code across various states. He supervised providers across facilities and provided expertise to elected and appointed officials in local markets.

Dr. Gandotra began his Addiction career in public health serving an underserved community in Washington DC where he developed his perspective of how a nationwide approach to addiction treatment is greatly needed.

As Medical Director of Addiction Treatment Services at Johns Hopkins he directed patient care through implementation of department initiatives and medical center resources. Dr. Gandotra was tasked with both administrative and supervisory roles for all providers and clinics within Addiction Treatment Services.

At Johns Hopkins, he was responsible for developing program policy and procedure based on new research findings with the goal of improving outcomes and reducing risk for patients with substance use disorder. Dr. Gandotra has also worked as a Medical Director for federally qualified health centers where it was necessary to develop policies mindful of specific catchment area needs. In addition to his clinical work, Dr. Gandotra is a member of the American Society of Addiction Medicine and American Academy of Addiction Psychiatry.

Dr. Gandotra has worked with the Maryland State Attorney General on cases of physician misconduct, specifically those involving prescriptions of controlled substances. Dr. Gandotra also has been a consultant for the NFL player’s assistance program for substance use disorders. Dr. Gandotra received his medical degree from the Universidad Iberoamericana (UNIBE) School of Medicine and completed his Psychiatric residency at Howard University. He completed an Addiction Psychiatry Fellowship at Yale University School of Medicine.
Federal Agency Updates Plenary
Friday, May 29th from 9:45 a.m. – 12:15 p.m.

Elisabeth Houtsmuller, Ph.D.
Patient-Centered Outcomes Research Institute (PCORI)

Elisabeth (Els) Houtsmuller, PhD, is an Associate Director in the Healthcare Delivery and Disparities Research program at the Patient-Centered Outcomes Research Institute (PCORI).

Before joining PCORI, Houtsmuller served as managing editor of Health Technology Assessments (HTAs) at Hayes, Inc., leading a team of writers and the production of numerous HTAs on a wide range of medical and mental health topics. In addition, she led the Behavioral and Mental Health Services program at Hayes, Inc.

Earlier, Houtsmuller was an associate professor in the Department of Psychiatry at the Johns Hopkins University School of Medicine, where she served as principal investigator on several research grants, and directed a human subjects research laboratory focused on drug abuse and addiction. Her work has been published in numerous peer-reviewed papers, book chapters and health technology assessments.

Houtsmuller received a PhD in physiological psychology from Erasmus University in the Netherlands, and completed postdoctoral work at the Johns Hopkins University School of Medicine in Baltimore.
Federal Agency Updates Plenary
Friday, May 29th from 9:45 a.m. – 12:15 p.m.

Kurt Rasmussen, Ph.D.
National Institute on Drug Abuse (NIDA)

Kurt Rasmussen, Ph.D., is the Director of the Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse (NIDA), leading their efforts to promote the development of safe and effective pharmacotherapies, behavioral therapies, and devices to treat addiction. Previously he worked as a senior research scientist in the Neuroscience Division of Eli Lilly & Co., leading efforts to discover novel treatments for psychiatric disorders. He is a research scientist in the field of neuropharmacology and neurotherapeutic drug development with extensive experience in senior scientific and management leadership positions in the pharmaceutical industry and government.

Dr. Rasmussen's career spans 30 years of highly innovative scientific research in neuroscience pharmaceutical discovery, from hypothesis generation to clinical candidate evaluation. He is a Fellow of the American College of Neuropsychopharmacology and on the Editorial Board of Neuropsychopharmacology. He received his A.B. with honors and distinction from Cornell University, his Ph.D. in neuroscience and psychology from Princeton University, and was a postdoctoral associate in the Department of Psychiatry at the Yale University School of Medicine.
Clinical Updates in Psychopharmacology
Saturday, May 30th from 11:00 a.m. – 12:30 p.m.

Frances Levin, M.D.
New York State Psychiatric Institute and Columbia University

Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders at NYSPI/Columbia University. For over 20 years, she has been the Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital and for the past 14 years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic.

She is Medical Director of the Providers’ Clinical Support System- Medication Assisted Treatments (PCSS-MAT), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director of a SAMHSA-supported State Targeted Response technical assistance grant to states that received funding to address the national opioid epidemic.

She is the principal investigator on several federally funded grants, including a U54 Medications Development grant evaluating novel treatments for opiate and cannabis use disorders, a T32 NIDA funded Substance Abuse Research Fellowship, and a K24 Mid-Career Investigator Award and collaborates on several other grants. Her current research interests include pharmacologic and psychotherapeutic treatment interventions for cocaine, marijuana, and opioid use disorder, and treatment approaches for adults with substance use disorders and attention-deficit hyperactivity disorder along with other psychiatric illnesses. Dr. Levin has over 200 articles and book chapters on a wide range of topics including treatments of substance use disorders, assessment and treatment of co-occurring psychiatric illnesses and vulnerabilities associated with substance use disorders. She has served on several advisory panels and ad-hoc federal grant review groups and was as a member of the NIDA – Initial Review Group: Training and Career Development Subcommittee for 8 years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She is an editorial board member of three journals, past President of the American Academy of Addiction Psychiatry and past Chair of the APA Council on Addiction Psychiatry.
Clinical Updates in Psychopharmacology
Saturday, May 30th from 11:00 a.m. – 12:30 p.m.

Joseph Goldberg, M.D.
Icahn School of Medicine at Mount Sinai

Joseph F. Goldberg, MD is Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai. He attended college at the University of Chicago, graduate school in neuroscience at the University of Illinois, and medical school at Northwestern University. He completed his residency and chief residency in psychiatry, and fellowship in psychopharmacology, at the Payne Whitney Clinic, New York Presbyterian Hospital, where he later served on the faculty and was site Principal Investigator at Weill-Cornell Medical Center for the NIMH STEP-BD program. He has published over 200 peer-reviewed papers on topics related mainly to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology, most recently "Managing the Side Effects of Psychotropic Medications, 2nd edition" published in 2019 by American Psychiatric Publishing, and the forthcoming “Practical Psychopharmacology” by Cambridge University Press. He serves on the Board of Directors for the American Society of Clinical Psychopharmacology and is an editor or on the editorial boards for a number of peer-reviewed journals. His research has been awarded funding from NARSAD, NIMH, the Stanley Foundation, and the American Foundation for Suicide Prevention. Dr. Goldberg is a Distinguished Fellow of the American Psychiatric Association and has been listed for many years in Best Doctors in America and Castle Connolly's "America's Top Doctors."
Clinical Updates in Psychopharmacology
Saturday, May 30th from 11:00 a.m. – 12:30 p.m.

Boadie Dunlop, M.D.
Emory University

Dr. Boadie Dunlop is Associate Professor and Director of the Mood and Anxiety Disorders Program (MAP) at Emory University. He graduated from Mayo Medical School in 1997, completed his Residency in Psychiatry at Emory in 2001 and became Director of MAP in 2006. His clinical research program is focused on the neurobiology, psychopharmacology, pharmacogenetics, and the personalized treatment of major depression, bipolar disorder, post-traumatic stress disorder, and anxiety disorders. He has served as an investigator for more than 70 clinical studies of medication and psychotherapy treatments for these conditions. He is currently the principal investigator of two National Institute of Mental Health grants examining neuroimaging and metabolomic predictors of outcome to treatments for major depressive disorder. Dr. Dunlop has authored fourteen book chapters and over 100 research papers in psychiatry and is a leader in the area of medication-assisted psychotherapy. In addition, he also serves as the course director for the Mood and Anxiety Disorders lecture series at Emory and provides supervision in psychopharmacology for Emory Psychiatry residents.
ACKNOWLEDGEMENTS

Steering Committee Chairs

Susan G. Kornstein, M.D.

Mark H. Rapaport, M.D.

Program Chairs

Erika Saunders, M.D.

Lee Cohen, M.D.

New Investigator Award Program Chairs

Mark H. Rapaport, M.D.

Christopher Sarampote, Ph.D.
Christoph U. Correll, M.D.
The Zucker Hillside Hospital

Lori Davis, M.D.
Tuscaloosa VA Medical Center

Michael Davis, M.D., Ph.D.
US Food and Drug Administration

Tiffany Farchione, M.D.
US Food and Drug Administration

Bruce Kinon, M.D.
Lundbeck

Scott Aaronson, M.D.*
Sheppard Pratt Health Systems

Mohammed Ahmed, M.D.
University of California, San Diego

Amit Anand, M.D.
Cleveland Clinic Lerner School of Medicine of Case Western University

Pratik Bahekar, M.D.
Yale-New Haven Psychiatric Hospital

Anahita Bassir Nia, M.D.*
Yale University School of Medicine

Isabelle Bauer, Ph.D.
University of Texas Health Science Center at Houston

Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Katharine Phillips, M.D.
Weill Cornell Medical College/New York-Presbyterian Hospital

Nina R. Schooler, Ph.D.
State University of New York, Downstate Medical Center

Holly A. Swartz, M.D.
University of Pittsburgh School of Medicine

Lawrence Cohen, Pharm.D.
University of North Texas Health Science Center

Lynn Crismon, Pharm.D.*
The University of Texas at Austin

Larry Culpepper, M.D., M.P.H.
Boston University

Cristina Cusin, M.D.
Massachusetts General Hospital

Maurizio Fava, M.D.
Massachusetts General Hospital

Bharathi Gadad, Ph.D.
Texas Tech University Health Science Center

New Investigator Alumni

*Representing ASCP CME Committee
★ Srinath Gopinath, M.D.
UCONN Health Center

Ahmad Hameed, M.D.
Pennsylvania State College of Medicine

Vikas Gupta, M.D., M.P.H.*
ECU

Usman Hameed, M.D.
Penn State Hersey Medical Center

Ahmad Hameed, M.D.
Penn State College of Medicine

★ Ebrahim Haroon, M.D.
Emory University School of Medicine

Michael Henry, M.D.
Massachusetts General Hospital

★ Dan Iosifescu, M.D.
Nathan S Kline Institute/New York University School of Medicine

★ Ayana Jordan, M.D., Ph.D.
Yale University School of Medicine

Susan Kornstein, M.D.
Virginia Commonwealth University

★ Rajnish Mago, M.D.*
Simple and Practical Mental Health

★ Tim Mariano, M.D., Ph.D.
Harvard Medical School

Sanjay Mathew, M.D.
Baylor College of Medicine

★ Brian Mickey, M.D., Ph.D.
University of Utah School of Medicine

★ Francisco Moreno, M.D.
University of Arizona

Charles Nemeroff, M.D., Ph.D.
The University of Texas At Austin

Minkyung Park, M.D.
UTSW Medical Center Dallas

Mark Pollack, M.D.
Rush University Medical Center

★ Rajiv Radhakrishnan, M.D.
Yale School of Medicine

Shamecca Scott, Psy.D.
MindSet, LLC

★ Jair Soares, M.D., Ph.D.
University of Texas School of Medicine at Houston

Oleg Tcheremissine, M.D.
Atrium Health

Antonio Teixeira, M.D.
University of Texas Health Science Center at Houston

★ Carlos A. Zarate, M.D.
National Institute of Mental Health

Mark Zimmerman, M.D.*
Brown University

★ New Investigator Alumni
★ Representing ASCP CME Committee
Ross Baker, Ph.D.
Otsuka Pharmaceuticals

Lee Cohen, M.D.
Massachusetts General Hospital

★ Ella Daly, M.D.
Johnson & Johnson PRD

★ Lori Davis, M.D.
Tuscaloosa VA Medical Center

Bryan Dirks, M.D.
ACADIA Pharmaceuticals Inc.

★ Tiffany Farchione, M.D.
US Food and Drug Administration

Marlene Freeman, M.D.
Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

David J. Kupfer, M.D.
University of Pittsburgh School of Medicine

Raye Litten, Ph.D.
National Institute of Alcohol Abuse and Alcoholism

Valentina Mantua, M.D.
Center for Drug Evaluation and Research, Food and Drug Administration

Stephen Marder, M.D.
Semel Institute at UCLA

Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

★ Francisco Moreno, M.D.
University of Arizona

Luca Pani, M.D.
University of Miami

Mark Pollack, M.D.
Myriad Neuroscience

Mark H. Rapaport, M.D.
Emory University School of Medicine

★ Erika Saunders, M.D.
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center

★ Holly Swartz, M.D.
University of Pittsburgh School of Medicine

★ Madhukar Trivedi, M.D.
University of Texas Southwestern Medical Center

★ New Investigator Alumni

*Representing ASCP CME Committee
Madhukar Trivedi, M.D. – ASCP President
UT Southwestern Medical Center

Michael E. Thase, M.D. – ASCP Past President
University of Pennsylvania

Leslie Citrome, M.D., M.P.H. – ASCP Treasurer and President Elect
New York Medical College

John Newcomer, M.D. – ASCP Past Treasurer
South Florida Behavioral Health Network

Trisha Suppes, M.D., Ph.D. - ASCP Treasurer Elect
Stanford University

Scott Aaronson, M.D.*
Sheppard Pratt Health System

Joseph Calabrese, M.D.
University Hospitals Cleveland Medical Center

Christoph U. Correll, M.D.
The Zucker Hillside Hospital

Kristina Deligiannidis, M.D.
Zucker Hillside Hospital; Feinstein Institute for Medical Research; Hofstra Northwell School of Medicine

Marlene Freeman, M.D.
Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

New Investigator Alumni

Joseph Goldberg, M.D.*
Icahn School of Medicine at Mount Sinai

John Kane, M.D.
The Zucker Hillside Hospital

Matthew Macaluso, D.O.
University of Kansas School of Medicine

Stephen Marder, M.D.
Semel Institute at UCLA

Sanjay Mathew, M.D.
Baylor College of Medicine

Francisco Moreno, M.D.
University of Arizona

George Papakostas, M.D.
Massachusetts General Hospital

Katharine Phillips, M.D.
Weill Cornell Medical College/New York-Presbyterian Hospital

Dan Iosifescu, M.D.
Nathan S Kline Institute/New York University School of Medicine

Susan Kornstein, M.D.
Virginia Commonwealth University, Board Member-elect

Holly Swartz, M.D.
University of Pittsburgh School of Medicine, Board Member-elect

*Representing ASCP CME Committee
ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

Intra-Cellular Therapies
Sunovion
Supernus
Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMeeting.org.

Continuing Education Credits are available for physicians, pharmacists, and psychologists. Self-assessment maintenance of certification credits are available for physicians. Applications for credit must be completed online with the meeting evaluation survey. The survey will be emailed to you at the completion of the meeting and will be available online at www.ASCPMeeting.org.

Surveys for continuing education credit must be submitted no later than Tuesday, June 30, 2020. It is the policy of the ASCP to require disclosure of financial relationships from individuals in a position to control the content of a CME activity; to identify and resolve conflicts of interest related to those relationships; and to make disclosure information available to the audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentations.

The American Board of Psychiatry and Neurology has reviewed the annual meeting and has approved this program as part of a comprehensive self-assessment program, which is mandated by the ABMS as a necessary component of maintenance of certification.

Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. For the enduring portion, you must complete the entire chosen session. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Society of Clinical Psychopharmacology (ASCP). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live and enduring material combination activity for a maximum of 26.0 AMA PRA Category 1 Credits™ (10.0 hours for live webinars and 16.0 hours for enduring material) for physicians and 26.0 knowledge-based hours (10.0 hours live webinars and 16.0 hours enduring material) for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity. NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the live activity or within 30 days of your completion of the enduring material activity to meet the deadline for submission to CPE Monitor.

Psychologists
This course is co-sponsored by Amedco and ASCP. Amedco is approved by the American Psychological Association to sponsor continuing education for psychologists. Amedco maintains responsibility for this program and its content. Maximum of 26.0 hours (10.0 hours live webinars and 16.0 hours enduring material). Continuing education credit available; see www.ascpmeeting.org for more details. Partial credit will not be awarded.

All participants who request continuing education credits by Tuesday, June 30, 2020, should expect to receive their statement of credits emailed to them immediately. MOC certificates will be emailed in July.

The Meeting Evaluation Survey will be available at www.ASCPMeeting.org. We encourage all registrants to complete the evaluation. Attendees requesting CME, MOC, or CE credits must complete the survey in order to obtain credits. Your candid input on the 2020 meeting is appreciated as we strive to improve the meeting each year.
ASCP is pleased to offer for the first time our 2020 ASCP Psychopharmacology Update: State-of-the-Art Spring Meeting lectures for free to all ASCP 2020 Annual Meeting Attendees. We are very excited to offer this new benefit featuring a wonderful lineup of nationally acclaimed speakers and topics.

**Ketamine and Glutamate Modulators in Mood Disorders: An Update**  
*Dan Iosifescu, M.D.*  
Nathan Kline Institute  
New York University School of Medicine

**Consensus-Based Recommendations for Clinicians on how to Assess and Address Cognitive Impairment in Bipolar Disorder (BD)**  
*Katherine Burdick, Ph.D.*  
Brigham & Women's Hospital  
Harvard Medical School

**Obesity and Its Treatment: Tackling a Rising Threat to Global Health**  
*Fatima Cody Stanford, M.D., M.P.H., M.P.A.*  
Massachusetts General Hospital

**Treatment of Posttraumatic Stress Disorder**  
*Tom Neylan, M.D.*  
University of California, San Francisco

**Neurostimulation 2020: Evolving Paradigm for Mood and Anxiety Disorders**  
*Scott Aaronson, M.D.*  
Sheppard Pratt Health System

**Bipolar Disorder in Pregnancy: Treatment Strategies**  
*Vivien Burt, M.D., Ph.D.*  
The David Geffen School of Medicine at UCLA

**For Vs. Against: Antidepressants for Bipolar Disorders**  
*Joseph Goldberg, M.D.*  
Icahn School of Medicine at Mount Sinai  
and  
*Andy Nierenberg, M.D.*  
Massachusetts General Hospital

**OCD Comorbid | Comorbid OCD**  
*Jamie Feusner, M.D.*  
UCLA Brain Research Institute

**The Psychopharmacology of Gun Violence**  
*Jack Rozel, M.D.*  
University of Pittsburgh Medical Center

**Translational Neuroscience for the Psychopharmacologist**  
*John Neumaier, M.D., Ph.D.*  
University of Washington

**Pharmacological Emergencies: When Prescribing Goes Bad**  
*Jose Maldonado, M.D.*  
Stanford University School of Medicine

**Polypharmacy in Schizophrenia**  
*Stephen Marder, M.D.*  
Semel Institute at UCLA

The recorded sessions can be found on the ASCP Annual Meeting website and are accessible to all registered attendees. You will receive an email with instructions on how to access the password-protected site. Presentation slides can be found in the back of the program book. For additional information, contact the ASCP Executive Office at info@ascpp.org.
2021 ASCP Annual Meeting
June 01 – 04, 2021

The 2021 ASCP Annual Meeting will take place at the Loews Miami Beach Hotel in Miami, Florida. Details regarding abstract submission for the 2021 Annual Meeting will be released in September 2020.
8:00 a.m. – 8:30 a.m. | Don Klein Memorial

8:30 a.m. – 9:30 a.m. | Telepsychiatry in the Age of COVID
Chair: Lee Cohen, Massachusetts General Hospital
Presenter: Jay Shore, University of Colorado Anschutz Medical Campus

9:30 a.m. – 9:45 a.m. | Break

9:45 a.m. – 12:15 p.m. | Federal Agency Updates
Chair: Madhukar Trivedi, UT Southwestern Medical Center
Presenters: Sarah Lisanby, NIMH; George Koob, NIAAA; Kurt Rasmussen, NIDA; Neeraj Gandotra, SAMHSA; Elisabeth Houtsmuller, PCORI

12:15 p.m. – 12:30 p.m. | Break

12:30 p.m. – 2:00 p.m. | *See all poster titles on page 32

2:00 p.m. – 2:15 p.m. | Break

2:15 p.m. – 3:45 p.m. | *Difficult to Treat Depression: What Are the Implications for Research and Practice?
Chair: A. John Rush, National University of Singapore
Presenters: A. John Rush, National University of Singapore; R. Hamish McAllister-Williams, Newcastle University; Larry Alphs, Janssen Scientific Affairs, LLC.; Madhukar Trivedi, UT Southwestern Medical Center

3:45 p.m. – 4:00 p.m. | Break

4:00 p.m. – 5:30 p.m. | *Public-Private Partnerships: Pathways to Schizophrenia Drug Development
Chair/Discussant: Linda Brady, DNBBS/NIMH/NIH
Presenters: Ken Duckworth, NAMI (National Alliance on Mental Illness); Linda Brady, DNBBS/NIMH/NIH; Kenneth Koblan, Sunovion Pharmaceuticals, Inc.; Michael Sand, Boehringer Ingelheim

5:30 p.m. – 6:00 p.m. | ASCP Business Meeting (ASCP Members Only)

6:00 p.m. – 7:00 p.m. | Conversation Hour with Leslie Citrome, M.D.

6:00 p.m. – 7:00 p.m. | Conversation Hour with Michael E. Thase, M.D.

6:00 p.m. – 7:00 p.m. | Conversation Hour with Madhukar Trivedi, M.D.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8:00 a.m. – 9:30 a.m. | *Clinical Utility of Targeting Anger and Irritability to Guide Novel Therapeutics for Patients with Depression  
**Co-Chairs:** Madhukar Trivedi, UT Southwestern Medical Center; Manish Jha, UT Southwestern  
**Presenters:** Manish Jha, UT Southwestern; James Murrough, Icahn School of Medicine at Mount Sinai; Cherise Chin Fatt, University of Texas Southwestern Medical Center; Maurizio Fava, Massachusetts General Hospital  
**Discussant:** Sanjay J. Mathew, Baylor College of Medicine & Michael E. DeBakey VA Medical Center |
| 9:30 a.m. – 9:45 a.m. | Break                                                                 |
| 9:45 a.m. – 10:45 a.m. | **AFSP/ASCP Panel Session**  
**Chair:** Madhukar Trivedi, UT Southwestern Medical Center  
**Presenters:** Madhukar Trivedi, UT Southwestern Medical Center; Jill Harkavy-Friedman, American Foundation for Suicide Prevention; William McCall, Medical College of Georgia, Augusta University |
| 10:45 a.m. – 11:00 a.m. | Break                                                                 |
| 11:00 a.m. – 12:30 p.m. | **Clinical Updates in Psychopharmacology Session**  
**Chair:** Erika Saunders, Penn State College of Medicine, Penn State Health  
**Presenters:** Frances Levin, New York State Psychiatric Institute and Columbia University; Joseph Goldberg, Icahn School of Medicine at Mount Sinai; Boadie Dunlop, Emory University |
| 12:30 p.m. – 12:45 p.m. | Break                                                                 |
| 12:45 p.m. – 2:15 p.m. | **Poster Session II**  
*See all poster titles on page 38 |
| 2:15 p.m. – 3:45 p.m. | **Assessing the Impact of Stimulants on Functional Outcomes in ADHD**  
**Chair:** Joseph Biederman, Massachusetts General Hospital  
**Presenters:** Ronna Fried, MGH/Harvard Medical School; Maura Disalvo, Massachusetts General Hospital; Joseph Biederman, Massachusetts General Hospital; Amos Adler, MEMOTEXT Corporation  
**Discussant:** Maurizio Fava, Massachusetts General Hospital |
| 3:45 p.m. – 5:45 p.m. | **Pharmaceutical Pipelines**  
**Co-Chairs:** Leslie Citrome, New York Medical College; Carlos Zarate, National Institute of Mental Health  
**Presenters:** Cedric O'Gorman, Axsome Therapeutics Inc.; Sanjay J. Mathew, Baylor College of Medicine & Michael E. DeBakey VA Medical Center; Hans Eriksson, COMPASS Pathways; Vinita Uttamsingh, Concert Pharmaceuticals, Inc.; Tong Lee, Genereys Biopharmaceuticals Corp.; Kenneth Koblin, Sunovion Pharmaceuticals, Inc.; Dragana Bugarski-Kirola, ACADIA Pharmaceuticals Inc.; Stephen Brannan, Karuna; David Donabedian, Brain |
8:00 a.m. – 8:30 a.m.  
Don Klein Memorial  
Remembering Don Klein, ASCP Founding Member. Dr. Klein spearheaded the first meeting organizing the society in May 1992, where he envisioned an organization for psychopharmacology practitioners dedicated to education, the exchange of information, CME, and the support of research.

8:30 a.m. – 9:30 a.m.  
COVID-19 PANEL  
Chair: Lee Cohen, Massachusetts General Hospital  
Telespsychiatry in the Age of Covid  
Jay Shore, University of Colorado Anschutz Medical Campus

9:30 a.m. – 9:45 a.m.  
Break

9:45 a.m. – 12:15 p.m.  
Federal Agency Updates  
Chair: Madhukar Trivedi, UT Southwestern Medical Center  
Introduction

9:45 a.m. – 9:55 a.m.  
An Update on Drug Development Efforts at NIMH  
Sarah Lisanby, NIH/NIMH

9:55 a.m. – 10:20 a.m.  
Evidence-Based Science Update on the Prevention, Diagnosis and Treatment of Alcohol Use Disorder From NIAAA  
George Koob, NIAAA

10:20 a.m. – 10:45 a.m.  
SAMHSA Updates: NSDUH Data, Ending the HIV Epidemic Efforts  
Neeraj Gandotra, SAMHSA

10:45 a.m. – 11:10 a.m.  
PCORI: Improving Outcomes Important to Patients  
Elisabeth Houtsman, PCORI

11:10 a.m. – 11:35 a.m.  
Drug Abuse and Addiction in America: Challenges and Opportunities  
Kurt Rasmussen, NIDA

11:35 a.m. – 12:00 p.m.  
Discussion

12:00 p.m. – 12:15 p.m.  
Break

12:15 p.m. – 12:30 p.m.  
Poster Session I

12:30 p.m. – 2:00 p.m.  
Break

2:00 p.m. – 2:15 p.m.  

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:15 p.m. – 3:45 p.m.</td>
<td><em>Difficult to Treat Depression: What Are the Implications for Research and Practice?</em></td>
<td>Chair: A. John Rush, National University of Singapore</td>
</tr>
<tr>
<td>2:15 p.m. – 2:25 p.m.</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>2:25 p.m. – 2:45 p.m.</td>
<td><em>The Identification, Assessment and Management of Difficult-To-Treat Depression: An International Consensus Model</em></td>
<td>R. Hamish McAllister-Williams, Newcastle University</td>
</tr>
<tr>
<td>2:45 p.m. – 3:05 p.m.</td>
<td><em>What Are the Implications for DTD for Clinically-Oriented Research?</em></td>
<td>A. John Rush, National University of Singapore</td>
</tr>
<tr>
<td>3:05 p.m. – 3:25 p.m.</td>
<td><em>What Are the Implications of DTD for Obtaining Regulatory Approval for New Mood Disorder Treatments?</em></td>
<td>Larry Alphs, Janssen Scientific Affairs, LLC</td>
</tr>
<tr>
<td>3:25 p.m. – 3:45 p.m.</td>
<td><em>The Role of Biomarkers in Difficult to Treat Depression</em></td>
<td>Madhukar Trivedi, UT Southwestern Medical Center</td>
</tr>
<tr>
<td>3:45 p.m. – 4:00 p.m.</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m. – 5:30 p.m.</td>
<td><em>Public-Private Partnerships: Pathways to Schizophrenia Drug Development</em></td>
<td>Chair: Linda Brady, DNBBS/NIMH/NIH</td>
</tr>
<tr>
<td>4:00 p.m. – 4:10 p.m.</td>
<td>Introduction</td>
<td></td>
</tr>
<tr>
<td>4:10 p.m. – 4:25 p.m.</td>
<td><em>Advocacy Organizations: Catalysts in Fostering Public-Private Partnerships</em></td>
<td>Ken Duckworth, NAMI (National Alliance on Mental Illness)</td>
</tr>
<tr>
<td>4:25 p.m. – 4:40 p.m.</td>
<td><em>Initiatives to Enable Early Intervention in Schizophrenia</em></td>
<td>Linda Brady, DNBBS/NIMH/NIH</td>
</tr>
<tr>
<td>4:40 p.m. – 4:55 p.m.</td>
<td><em>Leveraging Public-Private Partnerships: Development of SEP-363856, a Novel Non-Dopamine D2 Receptor Blockade Treatment for Schizophrenia</em></td>
<td>Kenneth Koblan, Sunovion Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>4:55 p.m. – 5:10 p.m.</td>
<td><em>The Importance of External Collaboration in Developing Drugs for Serious Mental Illness</em></td>
<td>Michael Sand, Boehringer Ingelheim</td>
</tr>
<tr>
<td>5:10 p.m. – 5:30 p.m.</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>5:30 p.m. – 6:00 p.m.</td>
<td>ASCP Business Meeting (ASCP Members Only)</td>
<td></td>
</tr>
<tr>
<td>6:00 p.m. – 7:00 p.m.</td>
<td>Conversation Hour with Leslie Citrome, M.D.</td>
<td></td>
</tr>
<tr>
<td>6:00 p.m. – 7:00 p.m.</td>
<td>Conversation Hour with Michael E. Thase, M.D.</td>
<td></td>
</tr>
<tr>
<td>6:00 p.m. – 7:00 p.m.</td>
<td>Conversation Hour with Madhukar Trivedi, M.D.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 8:00 a.m. – 9:30 a.m. | *Clinical Utility of Targeting Anger and Irritability to Guide Novel Therapeutics for Patients with Depression  
Co-Chairs: Madhukar Trivedi, UT Southwestern Medical Center; Manish Jha, UT Southwestern  
Discussant: Sanjay Mathew, Baylor College of Medicine & Michael E. DeBakey VA Medical Center |
| 8:00 a.m. – 8:10 a.m. | Introduction                                                          |
| 8:10 a.m. - 8:25 a.m. | Association Between Irritability and Suicidality: Findings from Four Clinical Trials of Adults with Major Depressive Disorder or Stimulant Use Disorder  
Manish Jha, UT Southwestern |
| 8:25 a.m. - 8:40 a.m. | Novel Therapeutics for Irritability in Patients With Mood Disorder  
James Murrough, Icahn School of Medicine at Mount Sinai |
| 8:40 a.m. - 8:55 a.m. | Elucidating Neural Correlates of Irritability in Adults With Major Depressive Disorder: Findings From the EMBARC Study  
Cherise Chin Fatt, University of Texas Southwestern Medical Center |
| 8:55 a.m. - 9:10 a.m. | Irritability and Anger Attacks in Major Depressive Disorder  
Maurizio Fava, Massachusetts General Hospital |
| 9:10 a.m. – 9:30 a.m. | Discussion                                                            |
| 9:30 a.m. – 9:45 a.m. | Break                                                                |
| 9:45 a.m. – 10:45 a.m. | ASCP/AFSP Panel  
Madhukar Trivedi, UT Southwestern Medical Center |
| 9:45 a.m. – 9:55 a.m. | Introduction                                                          |
| 9:55 a.m. – 10:10 a.m. | ASCP/AFSCP Panel  
Madhukar Trivedi, UT Southwestern Medical Center |
| 10:10 a.m. – 10:25 a.m. | Clinical Trials for Suicide prevention: Importance and Considerations  
Jill Harkavy-Friedman, American Foundation for Suicide Prevention |
| 10:25 a.m. – 10:40 a.m. | Lessons Learned from a Small Pilot Randomized Controlled Trial of Prazosin in PTSD Nightmare Sufferers with Suicidality  
William McCall, Medical College of Georgia; Augusta University |
| 10:45 a.m. – 11:00 a.m. | Break                                                                |
11:00 a.m. – 12:30 p.m.  *Clinical Updates in Psychopharmacology Session*
Chair: Erika Saunders, Penn State College of Medicine, Penn State Health

11:10 a.m. – 11:35 a.m.  Introduction

11:10 a.m. – 11:35 a.m.  **Comorbid ADHD and SUD**
Frances Levin, New York State Psychiatric Institute and Columbia University

11:35 a.m. – 12:00 p.m.  **Recent Pharmacotherapy Advances in Bipolar Disorder**
Joseph Goldberg, Icahn School of Medicine at Mount Sinai

12:00 p.m. – 12:25 p.m.  **Overview of Pharmacogenomic Testing for Major Depressive Disorder**
Boadie Dunlop, Emory University

12:30 p.m. – 12:45 p.m.  Break

12:45 p.m. – 2:15 p.m.  Poster Session

12:45 p.m. – 2:15 p.m.  *Assessing the Impact of Stimulants on Functional Outcomes in ADHD*
Chair: Joseph Biederman, Massachusetts General Hospital
Discussant: Maurizio Fava, Massachusetts General Hospital

2:15 p.m. – 2:25 p.m.  Introduction

2:25 p.m. - 2:40 p.m.  **A Systematic Literature Review and Meta-Analysis Examining the Effects of Medications for ADHD on Functional Outcomes Using Data From Registry and Large Datasets Based Studies**
Ronna Fried, MGH/Harvard Medical School

2:40 p.m. - 2:55 p.m.  **Quantifying the Protective Effects of Stimulants on Functional Outcomes in ADHD: A Focus on Number Needed to Treat (NNT) Statistic and Sex Effects**
Maura Disalvo, Massachusetts General Hospital

2:55 p.m. - 3:10 p.m.  **Further Evidence of Low Adherence to Stimulant Treatment in Adult ADHD: An Electronic Medical Records Study**
Joseph Biederman, Massachusetts General Hospital

3:10 p.m. - 3:25 p.m.  **An Innovative SMS Intervention to Improve Adherence to Stimulants in Children with ADHD: Preliminary Findings**
Amos Adler, MEMOTEXT Corporation

3:25 p.m. – 3:45 p.m.  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 p.m. – 5:45 p.m.</td>
<td><strong>Pharmaceutical Pipelines</strong>&lt;br&gt;Co-Chairs: Leslie Citrome, New York Medical College; Carlos Zarate, National Institute of Mental Health</td>
</tr>
<tr>
<td>3:45 p.m. – 3:55 p.m.</td>
<td>Introduction</td>
</tr>
<tr>
<td>3:55 p.m. – 4:05 p.m.</td>
<td><strong>Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial</strong>&lt;br&gt;Cedric O’Gorman, Axsome Therapeutics Inc.</td>
</tr>
<tr>
<td>4:05 p.m. – 4:15 p.m.</td>
<td><strong>Effect of the NMDAR Antagonist Lanicemine (BHV-5500) on Startle Reactivity, Gamma Oscillatory Response, and Hyperarousal in PTSD</strong>&lt;br&gt;Sanjay J. Mathew, Baylor College of Medicine &amp; Michael E. DeBakey VA Medical Center</td>
</tr>
<tr>
<td>4:15 p.m. – 4:25 p.m.</td>
<td><strong>Psilocybin Therapy for Treatment-Resistant Depression: Results From a Phase I, Double-Blind, Placebo-Controlled Trial With Exploratory Efficacy Measures</strong>&lt;br&gt;Hans Eriksson, COMPASS Pathways</td>
</tr>
<tr>
<td>4:25 p.m. – 4:35 p.m.</td>
<td><strong>The Pharmacokinetic and Safety Profile of CTP-692 (Deuterated D-Serine) in Healthy Volunteers: Phase 1 Program Results</strong>&lt;br&gt;Vinita Uttamsingh, Concert Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>4:35 p.m. – 4:45 p.m.</td>
<td><strong>A Combination Drug Candidate for Treatment of Substance Use Disorders</strong>&lt;br&gt;Tong Lee, Generys Biopharmaceuticals Corp.</td>
</tr>
<tr>
<td>4:45 p.m. – 4:55 p.m.</td>
<td><strong>SEP-363856: A Compound with a Non-D2 Receptor Mechanism of Action for the Treatment of Schizophrenia: Update</strong>&lt;br&gt;Kenneth Koblan, Sunovion Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>4:55 p.m. – 5:05 p.m.</td>
<td><strong>ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Negative Symptoms of Schizophrenia</strong>&lt;br&gt;Dragana Bugarski-Kirola, ACADIA Pharmaceuticals Inc.</td>
</tr>
<tr>
<td>5:05 p.m. – 5:15 p.m.</td>
<td><strong>KarXT (A Combination of the Cholinergic Agonist Xanomeline With Trospium to Enhance Tolerability), is Superior to Placebo in Patients With Schizophrenia: Phase 2 Clinical Trial Results</strong>&lt;br&gt;Stephen Brannan, Karuna</td>
</tr>
<tr>
<td>5:15 p.m. – 5:25 p.m.</td>
<td><strong>Harnessing the Gut-brain Axis to Develop Novel Central Nervous System (CNS) Therapeutics to Improve the Quality of Life for People With CNS Diseases and Disorders</strong>&lt;br&gt;David Donabedian, Brain</td>
</tr>
<tr>
<td>5:25 p.m. – 5:45 p.m.</td>
<td>Discussion</td>
</tr>
<tr>
<td>5:45 p.m.</td>
<td>Adjourn</td>
</tr>
</tbody>
</table>
1. Long-Term Efficacy and Safety of Lemborexant in Adults With Insomnia Disorder: Results Across 12 Months From SUNRISE-2
Margaret Moline, Eisai Co, Ltd.
Jane Yardley, Mikko Kärppä, Yuichi Inoue, Kate Pinner, Carlos Perdomo, Gleb Filippov, Kohei Ishikawa, Naoki Kubota, Margaret Moline*

2. Public Image and Sentiment Toward the Pharmaceutical Industry: What Can We Do to Reverse the Negative Trend?
Charles Wilcox, Praxis Research Consulting

3. Why Are We Switching? A Retrospective Chart Review Study of Reasons for Antipsychotic Switch Amongst First- and Second-Generation Antipsychotics
Kaksha Varma, The Zucker Hillside Hospital
Kaksha Varma*, Daniel Guinart, Nahal Talasazan, Georgios Schoretsanitis, John M. Kane

4. The Impact of Ginkgo Biloba on Mental Illness and Psychotropic Medications
Alex Mull, Nova Southeastern University
Alex Mull*, Nikolas Cirillo, Leah Spigelman

5. Understanding the Adoption of Digital Medicines in Behavioral Health Clinic Settings: An Implementation Science Approach
Felicia Forma, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Suepattra May, Felicia Forma*, Meaghan Roach, Caroline Huber, Jason Shafrin, Dusica Hadzi Boskovic

6. Wearable Devices for the Real-Time Capture of Gait and Actigraphy Measures: Preliminary Feasibility and Validity Data in Older Adults With and Without Subjective Cognitive Decline
Alexandra Atkins, VeraSci
William Horan, Alexandra Atkins, Michael Kraus, Jared Linthicum, Angela Docter, Richard Keefe, Alexandra Atkins*

7. Language and Communication in Psychosis: Digital Tools as Novel Opportunities for Biomarker and Intervention
Sunny Tang, Zucker School of Medicine at Hofstra/Northwell

8. Phase 1 Pharmacokinetic Study of a Once-Daily Formulation of TNX-601 CR (Tianeptine Oxalate Controlled-Release) Tablets
Gregory Sullivan, Tonix Pharmaceuticals, Inc.
Gregory Sullivan*, Siobhan Fogarty, Regina Kiu, Bernd Meibohm, Seth Lederman

9. Psychometric Evaluation of a Computer-Administered Cognitive Test Battery in Patients With Major Depressive Disorder: Results From a Randomized, Multicenter, Crossover Study
Randall Morrison, Ortho-McNeil Janssen Scientific Affairs
Jennifer Bogert, Hany Rofael, Kenneth Mosca, Rachel Ochs Ross, Geert Callaerts, Daniel Wang, Judith Jaeger, Vaibhav Narayan, Wayne C. Drevets, Randall Morrison*

10. Next-Step Treatment Considerations in Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine
Sagar Parikh, University of Michigan
Sagar Parikh*, Patricio Riva-Possie, Fernando Goes, William Bobo

11. OPEN BOARD
12. Esketamine, in Conjunction With Antidepressant Monotherapy or Augmentation Therapy, Reduces Depressive Symptoms in Patients With Major Depressive Disorder and Active Suicidal Ideation With Intent
Karimah S. Bell Lynum, Janssen Scientific Affairs
Karimah S. Bell Lynum*, Abigail Nash, Carla Canuso, Dong Jing Fu, Dawn F. Ionescu, Jennifer Kern-Sliwa, Ibrahim Turkoz

13. Characteristics of Responders/Remitters in a Phase 4 Study of Adults with Major Depressive Disorder Treated with Vortioxetine 10 Mg
Venkatesha Murthy, Takeda Pharmaceuticals International, Inc.
Venkatesha Murthy*, Elizabeth Hanson, Paula Jacobsen, Rengyi Xu, Jingtao Wu

14. Efficacy and Safety of Vortioxetine (5, 10, and 20 mg) in Relapse Prevention: Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study in Adults With Major Depressive Disorder (MDD)
Michael Thase, Perelman School of Medicine at the University of Pennsylvania
Michael Thase*, Elizabeth Hanson, Paula Jacobsen, Rengyi Xu, Venkatesha Murthy

15. Switching to an Mao-I in the Setting of Treatment-Resistant Depression (TRD)
Kamron Fariba, Palm Beach Consortium
Kamron Fariba*, Anokh Sohol

H. Lynn Starr, Janssen Scientific Affairs, LLC
H. Lynn Starr*, Tina Vatanapradit, Karimah S. Bell Lynum, Isaac Nuamah, Lew Manera, Sherry Fua, Ella Daly

17. Characterizing Primary Care Pathways for Patients With a Depressive Disorder
Debra Lawrence, Takeda Pharmaceuticals North America, Inc.
Sharon Larson, Andrei Nemoianu, Debra Lawrence*, Melissa Troup, Michael Gionfriddo, Faisal Riaz, Haiyan Sun, Eric Wagner, Lambros Chrones, Sheetal Patel, Maelys Touya

18. Effect of Adjunctive Pimavanserin on Suicidality in Patients With Major Depression: Secondary Analysis From Clarity
Bryan Dirks, ACADIA Pharmaceuticals Inc
Richard C. Shelton, Maurizio Fava, Marlene P. Freeman, Michael E. Thase, George I. Papakostas, Manish K. Jha, Madhukar H. Trivedi, Bryan Dirks*, Keith Liu, Susan Legacy, Srdjan Stankovic

19. Implementation and Evaluation of a Care Management Model for Psychopharmacological Treatment in Primary Care
Alexander Lengerich, James A Haley Veteran's Hospital
Alexander Lengerich*, Benjamin Lord, Zachary Zuschlag

20. Sustained Remission in a Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial of Zuranolone (SAGE-217) in Postpartum Depression
Akanksha Mittal, Sage Therapeutics, Inc.
Akanksha Mittal*, Ming-Yi Huang, Ellison Suthoff, Sarah Acaster, Moshe Fridman, Sigui Li, Handan Gunduz-Bruce, Robert Lasser, Andrew Campbell, Vijayveer Bonthapally, Paul Hodgkins, Stephen J. Kanes, Kristina M. Deligiannis

21. Use of Clinical Global Impressions-Severity (CGI-S) to Assess Relapse During Maintenance Antidepressant Treatment in Patients With Treatment-Resistant Depression
Qiaoyi Zhang, Janssen Research & Development, LLC
Joachim Morrens, Maju Mathews, Vanina Popova, Ella J. Daly, Stephane Borentain, Benoît Rive, Beatriz Gonzalez Martin Moro, Carol Jamieson, Qiaoyi Zhang*

22. Knowledge, Attitude and Practice of Medical Students/Physicians towards American Geriatric Society Updated Beers Criteria 2019 for Potentially Inappropriate Medication Use in Older Adults
Rakesh Kumar, Guru Govind Singh Medical College
Rakesh Kumar*, Rishab Sharma, Richa Bansal

23. Hepatitis C Screening and Education of Acute Psychiatric Inpatients
Anita Kablinger, Carilion Clinic-VTC SOM
Anita Kablinger*, Marrieth Rubio, Daniela Hoch, William Rea
24. Pathways to Nonmedical Use of Prescription Stimulants in the General Population
Jody Green, Inflexxion, an IBH Company
Jody Green*, Stephen V. Faraone, Anthony Rostain, Jeffrey Newcorn

25. Project RockSTARR: Fostering Connections to Advocacy
Luke Kramer, The STARR Coalition

26. Impact of eCOA and Independent Review of Recorded PANSS Interviews on a Measure of Data Quality in Schizophrenia Clinical Trials
David Daniel, Bracket Global, LLC
David Daniel*, Xingmei Wang, Alan Kott

27. Neuropsychological Assessment Discriminates ADHD-I From SCT by Parent Report
Beth Krone, Mt. Sinai School of Medicine of the City University of New York
Beth Krone*, Anne Claude Bedard, Logan Downes, Quinn Downes, Amanda Kirschenbaum, Iliyan Ivanov, Kurt Schulz, Jeffrey Newcorn

28. Cognitive Performance and Psychedelic Effects Following Single and Multiple Ascending Doses of a New Cannabis Formulation (PPP001) Administered by Smoking/Inhalation in Male and Female Volunteers
Beatrice Setnik, Altasciences
Beatrice Setnik*, Jade Huguet, Catherine Mills, Randy Ringuette, Charles Campbell, Aurelia De Pauw, Eric Sicard, Guy Chamberland

29. An Examination of Combinatorial Pharmacogenetics Testing in Adolescent Depression: Results from a Double-Blind, Randomized, Controlled Effectiveness Trial
Jennifer Vande Voort, Mayo Clinic
Jennifer Vande Voort*, Scott Orth, Julia Shekunov, Magdalena Romanowicz, Jessica Ward, Nicole Leibman, Mark Frye, Paul Croarkin

30. Assessing the Benefit-Risk Ratio of Approved Treatments for Bipolar Depression Using Likelihood to Be Helped or Harmed (LHH) Analyses
Michael Tocco, Sunovion Pharmaceuticals, Inc.
Leslie Citrome, Michael Tocco*, Courtney Zeni, Andrei Pikalov, Robert Goldman

31. Effect of Lurasidone on Manic Symptoms and Treatment-Emergent Mania in Adult and Pediatric Populations With Bipolar Depression
Michael Tocco, Sunovion Pharmaceuticals, Inc.
Michael Tocco*, Andrei Pikalov, Courtney Zeni, Robert Goldman

32. An Assessment of QTC Effects With SPN-812 (Viloxazine Extended Release) in Healthy Adults
Greg Busse, Supernus Pharmaceuticals, Medical Affairs
Azmi Nasser, Shamia Faison, Tesfaye Liranso, Toyin Adewole, Maurizio Fava, Greg Busse*, Robert Kleiman, Stefan Schwabe

33. Toward Development of an Abbreviated PANSS for Pediatric Trials: Secondary Analyses of TEOSS and Other Psychopharmacologic Data Sets
Joan Busner, Signant Health
Joan Busner*, Eric Youngstrom, David Daniel, Robert Findling

34. Palatability Assessment of a New Amphetamine Extended-Release Tablet Formulation
William Seidel, Tris Pharma, Inc.
Antonio Pardo, Thomas King, William Seidel*, Judith Kando

35. The Clinical Impact of CBD on Psychiatric Disorders
Thersilla Oberbarnscheidt, University of Pittsburgh Medical Center, Western Psychiatric Hospital

36. Co-Occurring Cannabis Use in First-Episode Psychosis: Rationale for Treatment With Naltrexone and Proposed Study Design
Moein Foroughi, SUNY Downstate Medical Center
Moein Foroughi*, Nina Schooler
37. Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicidal Ideation With Intent: ASPIRE I and II
Dong Jing Fu, Janssen Research & Development, LLC
Dong Jing Fu*, Dawn F. Ionescu, Rosanne Lane, Pilar Lim, David Hough, Wayne Drevets, Husseini Manji, Carla M. Canuso

38. CTP-692, a Novel Deuterium-Modified D-Serine, Produces Higher Brain Exposure in Rats Compared to D-Serine
Christopher Brummel, Concert Pharmaceuticals
Christopher Brummel*, Sunanda Vedananda, Richard Gallegos, Julie Liu, Ye Lu, Darren H Wong, James Cassella

39. Reduction of Mood Variability via Nutritional Intervention for Bipolar Disorder: A Focus on Fatty Acids
Sarah S. Shahriar, Penn State Milton S. Hershey Medical Center
Sarah S. Shahriar*, Erika F.H. Saunders, Tiffany Myers, Emily Wasserman, Ming Wang, Ahmad Hameed, Venkatesh Basappa Krishnamurthy, Stanley Rapoport, Beth MacIntosh, Christopher E. Ramsden, Dahlia Mukherjee

40. Risk of Neuroleptic Malignant Syndrome With Vesicular Monoamine Transporter Inhibitors
Stanley Caroff, Perelman School of Medicine University of Pennsylvania

41. Those Who Fail to Learn From History Are Condemned to Repeat (Entering Bad Subjects)
Thomas Shiovitz, California Neuroscience Research
Thomas Shiovitz*, Brittany Steinmiller, Chelsea Steinmetz, Jasmin Regalado

42. OPEN BOARD

43. The Placebo-Control Reminder Script in Depression and Psychosis Trials: An Antidote for the Placebo and Nocebo Response
Elan Cohen, Hassman Research Institute
Elan Cohen*, Howard Hassman, David Walling, Katarzyna Wyka, William Horan, Richard S.E. Keefe, Vera Grindell, Steve Glass, Roberta Ball, John Styczynski, Jaclyn Lobb, Larry Ereshefsky

44. The Efficacy and Safety of Aripiprazole Once-Monthly 400mg (AOM 400) in African American/Black Patients Compared to Non-African American/Black Patients
Stephen Murray, Otsuka Pharmaceutical Development & Commercialization, Inc.
Stephen Murray*, Cathy Zhao, Pedro Such, Ross A. Baker, Maxine Chen, Jessica Madera

45. Examining Depressive Symptoms Across DSM Indications: Treatment Effects of Brexpiprazole in Patients With Major Depressive Disorder and Schizophrenia
Ruth A. Duffy, Otsuka Pharmaceutical Development and Commercialization, Inc.
Malaak Brubaker, Catherine Weiss, Stine R. Meehan, Dalei Chen, Ross A. Baker, Anna Eramo, Ruth A. Duffy*

46. Innovative Psychopharmacology in Treatment-Refractory Patient Population in Psychiatry
Mujeeb Shad, Oregon Health & Science University

47. Long-Term Safety of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 2 and 3 Studies
Vasudev Bhupathi, Alkermes, Inc.
Vasudev Bhupathi*, Bei Yu, Christine Graham, Lauren DiPetrillo, Jiani Yin, Asli Memisoglu, David McDonnell

48. Cardiometabolic Safety of Lumateperone (ITI-007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study
Andrew Satlin, Intra-Cellular Therapies
Andrew Satlin*, Suresh Durgam, Kimberly E Vanover, Robert E Davis, Bradford Loo, Richard Chen, Sharon Mates, Christoph Correll

49. Less is More: Deprescribing Anticholinergics in Patients With Severe Mental Illness
Jessica Gannon, University of Pittsburgh School of Medicine
Jessica Gannon*, Ana Lupu, Kathryn MacCamay, Jaspreet Brar, Roy Chengappa
50. Effects of Brexpiprazole on Patient Engagement and Functioning in Schizophrenia
Stine Meehan, H. Lundbeck A/S
Stine Meehan*, Lily Shi, Anne M. Pedersen, Catherine Weiss

51. Effect of Treatment with SEP-363856 on Measures of Cognition and Social Functioning in Patients With Schizophrenia
Kenneth Koblan, Sunovion Pharmaceuticals, Inc.
Snezana Milanovic, Ajay Origala, Heather Dworak, Seth C. Hopkins, Kenneth Koblan*

52. Long-Term Weight and Metabolic Effects of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses From Phase 3 Studies
Christine Graham, Alkermes, Inc.
John Newcomer, Ying Jiang, Lauren DiPetrillo, Sergey Yagoda, Bei Yu, David McDonnell, Christine Graham*

53. An Exploratory Analysis of BNSS and PANSS Negative Symptom Factor Item Correlations
Alan Kott, Signant Health
Alan Kott*, David Daniel

54. Long-Term Antipsychotic Efficacy of Olanzapine and Samidorphan Combination in Patients With Schizophrenia: Pooled Analyses from Phase 3 Studies
David McDonnell, Alkermes Pharma Ireland Ltd.
Rene Kahn, Christine Graham, Ying Jiang, Lauren DiPetrillo, Sergey Yagoda, David McDonnell*

55. Phase 3 Safety and Tolerability Results of the Combination Olanzapine and Samidorphan in Patients With Schizophrenia: The 1 Year ENLIGHTEN-2-Extension
Adam Simmons, Alkermes, Inc.
Rene Kahn, Bernard Silverman, Lauren DiPetrillo, Christine Graham, Ying Jiang, Jiani Yin, Adam Simmons*, Bei Yu, Craig Hopkinson, David McDonnell

56. The National Pregnancy Registry for Psychiatric Medications: Effects of Fetal Exposure to Atypical Antipsychotics on Risk for Major Malformations
Lee Cohen, Massachusetts General Hospital
Lee Cohen*, Marlene Freeman, Lina Goez-Mogollon, Sara McElheny, Taylor Church, Amanda Young, Phoebe Caplin, David Chitayat, Sonia Hernández-Díaz, Adele Viguera

57. Efficacy and Safety of Lumateperone (ITI-007) in the Treatment of Depressive Episodes Associated With Bipolar I and II Disorders
Suresh Durgam, Intra-Cellular Therapies, Inc.
Suresh Durgam*, Andrew Satlin, Kimberly E. Vanover, Robert E. Davis, Susan G. Kozauer, Jason Huo, Sharon Mates, Joseph Calabrese

58. Neurobehavioral Profile of a Human NMDA Receptor Null Allele
Brian Mickey, University of Utah School of Medicine
Brian Mickey*, Katherine Warthen, Margit Burmeister

59. OPEN BOARD

60. Differential Effects of Childhood vs. Adulthood Trauma in Cannabinoid Receptor Type 1 (CB1R) Availability in Post-Traumatic Stress Disorder (PTSD): A Review of Literature and Pilot Positron Emission Tomography (PET) Study
Anahita Bassir Nia, Yale University School of Medicine
Anahita Bassir Nia*, Cyril D'Souza, Kelly Cosgrove, Robert Pietrzak, Ilan Harpaz-Rotem

61. Adolescent Depression Symptom Clustering: Unsupervised Machine Learning Approaches
Eric Lin, Yale
Eric Lin*, Victor Avila, Jose Flores, Michael Bloch

62. Brugada Syndrome and Related Cardiac Conduction Disorders: A Strategy to Understand the Etiology of Sudden Cardiac Death Among Patients With Schizophrenia and Psychotic Bipolar Disorder
Rishab Gupta, SUNY Downstate Medical Center
Rishab Gupta*, Tim Bigdeli, Mihaela Aslan, Philip Harvey, Ayman Fanous, Nina Schooler

63. Are Patients with Schizophrenia Better off With Lifetime Antipsychotic Medication?: Replication of a Naturalistic, Long-Term, Follow-Up Study of Antipsychotic Treatment
Ira Glick, Stanford University School of Medicine
Ira Glick*, John Davis
64. Impact of Lemborexant Treatment on Patient-Reported Distress With Sleep and Interference With Daily Functioning Over 6 Months: Results From SUNRISE-2
Craig Chepke, UNC School of Medicine
Craig Chepke*, Rakesh Jain, Kate Pinner, Jane Yardley, Margaret Moline, Norman Atkins, Jr., Manoj Malhotra

65. Pimavanserin for the Treatment of Comorbid Depression in Patients With Parkinson’s Disease
Gustavo Alva, Neuroscience University of California at Riverside
Daryl DeKarske, Gustavo Alva*, Jason L. Aldred, Bruce Coate, Marc Cantillon, Victor Abler

66. Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Acute Schizophrenia: ALPINE Study Exploratory Efficacy and Patient-Reported Outcomes
Amy Claxton, Alkermes
Henry Nasrallah, David Walling, Peter J. Weiden, Yangchun Du, Baiyun Yao, Sergey Yagoda, Amy Claxton*

67. The Integration of a Computer-Based Functional Skills Training Program in Inpatients With Chronic Schizophrenia
McKenzie Osborne, Manhattan Psychiatric Center
McKenzie Osborne*, Anzalee Khan, Jean-Pierre Lindenmayer, Beverly Insel, Abraham Goldring, Phil Harvey
1. Translation and Cultural Adaptation of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) for Assessment of Functioning in Global Clinical Trials in German, Italian, Russian, Polish and Spanish for the U.S.
Alexandra Atkins, VeraSci
Alexandra Atkins*, William Horan, Heather Dickerson, Maren Hamby, Erika Scheib, Ryan Cartier, Richard S.E. Keefe

2. Seroquel Might Need a New Black Box Warning
Simona Morosan, University of Medicine and Pharmacy Iuliu-Hatieganu
Simona Morosan*, Michael Haas Brophy

3. A Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics, and Cognitive Effects of SAGE-718
Stephen Kanes, Sage Therapeutics, Inc.
Aaron Koenig, Kevin Moynihan, Sigui Li, Jeffrey Wald, Ludmila Kryzhanovskaya, Irena Webster, Mike Lewis, Helen Colquhoun, Stephen Kanes*, James Doherty

4. Care Pathways Preceding Suicidal Ideation or Probable Suicide Attempt in Adult Patients With Major Depressive Disorder
Jennifer Voelker, Janssen
Maryia Zhdanava, Jennifer Voelker*, Dominic Pilon, Laura Morrison, Maude Vermette-Laforme, Patrick Lefebvre, Abigail Nash, Cheryl Neslusan

5. Increasing Show Rates for MDD Clinical Trial Screening Visits: The Impact of Scheduling Speed on Screening Visit Attendance
Miriam Evans, Adams Clinical
Miriam Evans*, Colin Sauder, Daniel Thorpe, Jenicka Engler, Dyanna Domilici

6. Effect of Adjunctive Pimavanserin on Insomnia and Function in Patients With Major Depressive Disorder: Secondary Analysis From Clarity
Bryan Dirks, ACADIA Pharmaceuticals Inc
Manish K. Jha, Maurizio Fava, Marlene P. Freeman, Michael E. Thase, George I. Papakostas, Richard C. Shelton, Madhukar H. Trivedi, Bryan Dirks*, Keith Liu, Susan Legacy, Srdjan Stankovic

7. Impact Analysis of Vortioxetine Dose Change among Remitters in a Randomized Withdrawal Design Study
Paula Jacobsen, Independent
Paula Jacobsen, Elizabeth Hanson, Rengyi Xu, Jingtao Wu, Venkatesha Murthy, Paula Jacobsen, Elizabeth Hanson, Paula Jacobsen*

8. Excessive Daytime Sleepiness Among Potential Clinical Trial Participants With Major Depressive Disorder
Colin Sauder, Adams Clinical
Colin Sauder*, Miriam Evans, Marecki Serena, Jenicka Engler, Dyanna Domilici

9. Effects of Adjunctive Brexpiprazole on Patient Engagement and Functioning in Major Depressive Disorder
Catherine Weiss, Otsuka Pharmaceutical Development & Commercialization, Inc.
Catherine Weiss*, Dalei Chen, Anne M. Pedersen, Stine R. Meehan

10. Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results from the GEMINI Phase 3, Double-Blind, Placebo-Controlled Trial
Cedric O’Gorman, Axsome Therapeutics Inc.
Cedric O’Gorman*, Amanda Jones, Dan Iosifescu, Herriot Tabuteau
11. Rapid Onset of Antidepressant Efficacy in Postpartum Depression RCTs by Multiple Measures in an Integrated Analysis of Brexanolone Injection With a Durable Benefit Observed at 30 Days Follow-up Versus Placebo
Stephen Kanes, Sage Therapeutics, Inc.
Samantha Meltzer-Brody, Robert Riesenberg, C. Neill Epperson, Kristina M. Deligiannidis, David Rubinow, Haihong Li, Brian Werneburg, Stephen Kanes*

12. Placebo Response Assessed by Pet-Mr Neuroimaging in Major Depressive Disorder - A Randomized, Double-Blind, Sequential Parallel Comparison Design Clinical Trial
Cristina Cusin, Massachusetts General Hospital
Cristina Cusin, Aava Jahan, Yoann Petibon, Marc Normandin, Dan Dillon, Emily Belleau, Ma Chao, Nathaniel Alpert, Georges ElFakhri, Jacob Hooker, David Crowley, Devon Brunner, Diego Pizzagalli, Maurizio Fava, Cristina Cusin*

13. Effect of Adjunctive Brexpiprazole on Sexual Functioning in MDD According to Concomitant antidepressant: Post Hoc Analysis of Four Short-Term Studies
Malaak Brubaker, Otsuka America Pharmaceuticals, Inc.
Catherine Weiss, Stine R Meehan, Malaak Brubaker*, Peter Zhang, Mary Hobart

14. Evaluation of Video-Based Administration of Clinical Outcome Assessments and Mobile Patient Reported Outcomes for Major Depressive Episode in a Telemedicine Research Model
Christopher Reist, Science 37
Christopher Reist*, Todd Adamson, Jason Bain, Raquel Engilman, Volkan Coskun

15. Long-Term Efficacy of Lurasidone in Pediatric Bipolar Depression: Response, Remission and Recovery
Michael Tocco, Sunovion Pharmaceuticals, Inc.
Manpreet Singh, Michael Tocco*, Edward Schweizer, Andrei Pikalov

16. Guiding Accurate and Timely Diagnosis of Bipolar Depression: A Novel Pragmatic Screening Tool for Identifying Patients With Bipolar Disorder
Mehul Patel, Allergan
Roger McIntyre, Prakash Masand, Mehul Patel*, Amanda Harrington, Patrick Gillard, Susan McElroy, Kate Sullivan, Brendan Montano, T. Michelle Brown, Lauren Nelson, Rakesh Jain

17. Clinical Outcomes of Long-Term Lithium-Therapy and Development of Thyroid Disease in Bipolar Disorder: A Longitudinal Study
Nicolas Nunez, Mood Fellowship

18. A Retrospective Study of the Adjunct Use of Gabapentin With Benzodiazepines for the Treatment of Benzodiazepine Withdrawal
Edison Leung, University of Texas Health Science Center at Houston McGovern Medical School
Edison Leung*, Catherine Change, Gregory Cervenka, Dalsu Baris, Hanjing Emily Wu

William Seidel, Tris Pharma
Antonio Pardo, Thomas King, William Seidel, Judith Kando, William Seidel*

Rachel Daut, Myriad Neuroscience
Rachel Daut*, Lisa Brown, Oliver Vranjkovic, James Li, Ken Yu, Talal Al Habbab, Holly Johnson, Krystal Brown, Michael Jablonski, Bryan Dechairo

Ira Glick, Stanford University School of Medicine
22. Development of a Child and Adolescent eCOA Guided Interview for the PANSS Interview for Assessing Psychosis in Clinical Trials
Joan Busner, Signant Health
Joan Busner*, David Daniel, Sarah Atkinson, Robert Findling

23. The Value of eConsent Across Therapeutic Indications
Joshua Gant, Otsuka (OPDC)
Debbie Profit, PhD, Christoph Koenen, MD, MBA, William Carson, MD, Leonard Chuck, MD, PhD, Candace Saldarini, MD, Josh Gant, MD, MPH, Merzu Belete, Hannah Glenny, Joshua Gant*

24. The Benefits and Costs of Changing Treatment Technique in Electroconvulsive Therapy Due to Insufficient Improvement of a Major Depressive Episode
Harold Sackeim, College of Physicians & Surgeons, Columbia University
Harold Sackeim*, Joan Prudic, Devangere Devanand, Mitchell Nobler, Roger Haskett, Benoit H. Mulsant, Peter Rosenquist, William V. McCall

25. Kratom a New Drug of Concern
Thersilla Oberbarnscheidt, University of Pittsburgh Medical Center, Western Psychiatric Hospital

26. The Pharmacokinetic and Safety Profile of CTP-692 (Deuterated D-Serine) in Healthy Volunteers: Phase 1 Program Results
Vinita Uttamsingh, Concert Pharmaceuticals, Inc.
Vinita Uttamsingh*, Emily McIntyre, Sunanda Vedananda, Christopher Brummel, Virginia Braman, James Cassella

27. Abuse Potential Considerations for Lemborexant, a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
Margaret Moline, Eisai Inc.
Margaret Moline*, Shoji Asakura, Carsten Beuckmann, Ishani Landry, Beatrice Setnik

Eva Katz, Janssen Research and Development
Eva Katz*, David Hough, Teodora Doherty, Rosanne Lane, Jaskaran Singh, Bennett Levitan

29. Effects of SEP-363856 on Negative Symptoms in Schizophrenia: Analysis of an Acute, Placebo-Controlled Trial of a Novel Psychotropic Agent Without Dopamine D2 Receptor Occupancy
Kenneth Koblan, Sunovion Pharmaceuticals, Inc.
Seth C. Hopkins, Ajay Origala, Antony Loebel, Kenneth Koblan*

William Horan, VeraSci
William Horan*, Alexandra Atkins, Luca Pani, Philip Harvey, Tim Clayton, Anzalee Khan, Caren Gadigian, Shane Baldwin, Richard Keefe

31. Effect of Lemborexant Treatment on Insomnia Disease Severity and Fatigue across 12 Months in SUNRISE-2
Norman Atkins, Jr., Eisai Inc.
Margaret Moline, Mikko Kärppä, Jane Yardley, Dinesh Kumar, Kate Pinner, Carlos Perdomo, Gleb Filippov, Norman Atkins, Jr.*

32. Chart Extraction/Clinician Survey Shows Symptom Impact and Favorable Treatment Outcomes With VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Ericha Franey, Neurocrine Biosciences, Inc.
Leslie Lundt, Ericha Franey*, Chirag Shah, Chuck Yonan
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Luke Kramer*, Patrick Hendry, Krista Armstrong, Jessica Barag, Corey Fowler, Nichole Gutierrez, Jill Harkavy-Friedman, Eli Perez, Kimberly Vanover</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>Qualitative Clinical Trial Exit Interviews Evaluating Treatment Benefit, Burden, and Satisfaction in Patients With Schizophrenia</td>
<td>Adam Simmons, Alkermes, Inc.</td>
<td>Mariacristina Castelli, Noven Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adam Simmons*, Julia Carpenter-Conlin, Leona Bessonova, Amy K. O’Sullivan, David McDonnell, Cory Saucier, Michelle K. White, April M. Foster, Jakob B. Bjorner, Olga Lapeyra, David P. Walling</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Christoph Correll, Kenneth Koblan*, Seth C. Hopkins, Justine Kent, Hailong Cheng, Robert Goldman, Antony Loebel</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Lurasidone in Adolescents With Schizophrenia: Remission and Recovery during 2 Years of Open-Label Treatment</td>
<td>Michael Tocco, Sunovion Pharmaceuticals, Inc.</td>
<td>Michael Tocco*, Andrei Pikalov, Ling Deng, Robert Goldman</td>
</tr>
<tr>
<td>38</td>
<td>Clozapine Utilization at the Veterans Health Administration</td>
<td>Zachary Zuschlag, James A. Haley Veterans Hospital</td>
<td>Edward Goldberg, Neurocrine Biosciences, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Zachary Zuschlag*, Christopher Fowler, Andrew Devendorf, Vanessa Panaite, Olga Efimova, Susan Schultz</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Gender Differences in the Receipt of Psychopharmacological Treatment Among Working-Age Residents With Schizophrenia in U.S. Nursing Homes</td>
<td>Yiyang Yuan, University of Massachusetts Medical School</td>
<td>Yiyang Yuan*, Kate Lapane, Christine Ulbricht</td>
</tr>
<tr>
<td>40</td>
<td>Pharmacokinetic Profile of Asenapine Transdermal System HP-3070: The First Antipsychotic Patch in the US</td>
<td>Mariacristina Castelli, Noven Pharmaceuticals, Inc.</td>
<td>Mariacristina Castelli*, Katsumi Suzuki, Marina Komaroff, Courtney Zeni, Leslie Citrome</td>
</tr>
<tr>
<td>42</td>
<td>3-OH Cyproheptadine for Nightmares and Posttraumatic Stress Disorder</td>
<td>Michael Brophy, Private Practice</td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Lithium Therapy and Its Clinical Correlates in Patients With Bipolar Disorder</td>
<td>Mehak Pahwa, Mayo Clinic</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mehak Pahwa*, Colin Colby, Boney Joseph, Nicolas Nunez, Marin Veldic, Katherine Moore, Hannah Betcher, Alfredo Cuellar-Barboza, Susan McElroy, Joanna Biernacka, Mark Frye, Francisco Romo- Nava, Balwinder Singh</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Real-World Evaluation of Patient Characteristics and Disease Management in Long-Term Valbenazine Treatment in Adults With Tardive Dyskinesia</td>
<td>Edward Goldberg, Neurocrine Biosciences, Inc.</td>
<td>Edward Goldberg, Neurocrine Biosciences, Inc.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Scott Siegert, Chuck Yonan, Nadia Longo, Helga Cratty, Maryanne Nicosia, John Sampalis, Tara Carmack, Rahul Dhanda, Chirag Shah, Angel Angelov, Edward Goldberg*</td>
<td></td>
</tr>
</tbody>
</table>
45. Drivers of Antipsychotic Discontinuation: A Retrospective Chart Review Study
Kaksha Varma, The Zucker Hillside Hospital
Nahal Talasazan, Daniel Guinart, Kaksha Varma*, Georgios Schoretsanitis, John M. Kane

46. Prescriber Attitudes, Experiences, and Proclivities Toward Digital Medicine and How They Influence Adoption of Digital Medicine Platforms
Charles Ruetsch, Health Analytics, LLC
Charles Ruetsch*, Dawn Velligan, Delbert Robinson, Chris Jaeger, William Carpenter, Tigwa Davis, Joshua N. Liberman, Jennifer Clerie, Heidi Waters, Felicia Forma

47. Investigation of Mobile Health (mHealth) Technologies in the Management of Depression: Ethical, Legal, and Regulatory Challenges
Efraim Keisari, University of Connecticut School of Medicine/UConn Health
Efraim Keisari*, Parit Patel, Bing Wang, Jayesh Kamath

48. Development and Validation of AI-Driven Monitoring of Intentional Medication Non-Adherence in Clinical Trials
Anzar Abbas, AiCure
Shaolei Feng, Lei Guan, Ryan Bardsley, Gabriella Hall, Anzar Abbas*, Laura Shafner, Isaac Galatzер-Levy

49. Comparison of Different Duration Regimens for Intravenous Racemic Ketamine: 100-Minute Versus 40-Minute Infusions for Refractory Unipolar or Bipolar Depression
Sagar Parikh, University of Michigan, Ann Arbor

50. Accumulation of Neuromelanin in Brains of Patients With Schizophrenia: A Systematic Review
Fumihiko Ueno, Centre for Addiction and Mental Health
Fumihiko Ueno*, Ariel Graff-Guerrero

51. Mediation of the Relationship Between Suicide and Sleep by Personality
Jessica Rohr, The Menninger Clinic
Jessica Rohr*, Katrina Rufino, Sanjay Mathew, Michelle Patriquin

52. An MRS Study in People With Remitted Psychotic Depression Compared to Controls Plus Examination of Effects of Olanzapine vs. Placebo: A Preliminary Analysis
Hideaki Tani, Centre for Addiction and Mental Health
Hideaki Tani*, Iska Moxon-Emre, Natalie Forde, Nicholas Neufeld, Kathleen Bingham, Ellen Whyte, Barnett Meyers, George Alexopoulos, Matthew Hoptman, Anthony Rothschild, Hiroyuki Uchida, Alastair Flint, Benoit Mulsant, Aristotle Voineskos

53. Validation of a Computerized Adaptive Assessment Tool for Severity of Psychotic Symptoms and Diagnostic Prediction
Daniel Guinart, The Zucker Hillside Hospital
Daniel Guinart*, Renato de Filippis, Stella Rosson, Bhagyashree Patil, Nahal Talasazan, Lara Prizgint, Robert Gibbons, John Kane

54. Patient-Reported Barriers Limiting Mental Health Care Among Adults With Major Depressive Disorder: A Nationwide Analysis Using National Survey on Drug Use and Health Data
Harsh Kuvadia, Integrated Resources Inc.
Harsh Kuvadia*, Qian Cai, Ella Daly, Jennifer Voelker, Nancy Connolly, John J. Sheehan, Samuel T. Wilkinson

55. Estimating Individualized Treatment Rules for Reducing Recidivism Among Criminal Justice-Involved Adults With Mental Illness
Lina Montoya, UC Berkeley
Lina Montoya*, Maya Petersen, Jennifer Skeem, Sharon Farrell
56. Metformin for Comorbid Glucose Dysregulation and Schizophrenia Spectrum Disorders: A Pilot Double-Blind Randomized Control Study
Sri Mahavir Agarwal, Centre for Addiction and Mental Health (CAMH)

57. The Impact of Major Depressive Disorder and Suicidal Ideation or Suicide Attempts on Caregivers: A Comparison of Direct and Indirect Costs and Absences Using Objectively Measured Real World Data
Harsh Kuvadia, Integrated Resources Inc.
Harsh Kuvadia*, Ian A. Beren, H. Lynn Starr, John J. Sheehan, Nathan L. Kleinman, Richard A. Brook

58. Co-Prescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes
Helene Altmann, University of Pittsburgh School of Medicine
Helene Altmann*, Sarah Stahl, Marie Anne Gebara, Eric Lenze, Benoit Mulsant, Daniel Blumberger, Charles Reynolds, Jordan Karp

59. A Mindfulness and Peer Mentoring Program to Improve Adherence to Medication Assisted Treatment for Opioid Use Disorders (The Mind and Mentors Program [MiM])
Mercy Mumba, University of Alabama
Mercy Mumba*, Lori Davis, Rebecca Allen, Andrea Glenn, George Mugoya, David Albright

60. Cortisol, Estradiol and Interleukin-6 Alterations in Peripartum Women Veterans From Pregnancy to Postpartum: A Pilot Investigation
Mercedes Szpunar, Department of Veterans Affairs, San Diego
Mercedes Szpunar*, Selena Baca, Sandra Braun, Richard Hauger, Ariel Lang

61. TSPAN5 Regulates Serotonin and Kynurenine Levels: Pharmacogenomic Mechanisms Related to Alcohol Use Disorder and Acamprosate Treatment Response
Ming-Fen Ho, Mayo Clinic
Ming-Fen Ho*, Cheng Zhang, Lingxin Zhang, Lixuan Wei, Ying Zhou, Irene Moon, Jennifer Geske, Doo-Sup Choi, Joanna Biernacka, Mark Frye, Victor Karpyak, Zhexing Wen, Hu Li, Richard Weinshilboum

62. Ketamine Modulates Fronto-Striatal Circuitry in Depressed and Healthy Individuals
Anahit Mkrtchian, National Institute of Mental Health
Anahit Mkrtchian*, Jennifer Evans, Christoph Kraus, Peixiong Yuan, Bashkim Kadriu, Allison Nugent, Jonathan Roiser, Carlos Zarate

63. Long-Term Evaluation of Open-Label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis
Clive Ballard, University of Exeter Medical School

64. Improvement and Durability in SAPS-PD Assessment Over 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
Stuart H. Isaacson, Florida International University Herbert Wertheim College of Medicine
Stuart H. Isaacson*, Bruce Coate, Victor Abler, Srdjan Stankovic

65. Cariprazine Demonstrates Broad Efficacy Across Symptoms and Subgroups in Patients With Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials
Willie Earley, Allergan
Lakshmi N. Yatham, Rakesh Jain, Roger S. McIntyre, Willie Earley*, Mehul Patel
66. Impact of Lemborexant Treatment Across 12 Months on Fatigue Severity and Sleep Outcomes in Subjects From SUNRISE-2 With Clinically Significant Fatigue at Baseline
Craig Chepke, UNC School of Medicine
Rakesh Jain, Craig Chepke*, Kate Pinner, Jane Yardley, Margaret Moline, Norman Atkins, Jr., Manoj Malhotra

67. The Effects of Concurrent Bilateral Transcranial Direct Current Stimulation and Computerized Auditory Training on Tone Matching Task Performance and Mismatch Negativity in Schizophrenia
Walter Dunn, West Los Angeles VA Medical Center/UCLA
Walter Dunn*, Jonathan Wynn, Yuri Rassovsky, Allan Wu, Marco Iacoboni, Gerhard Hellemann, Michael Green

68. Results of the Hummingbird Study a Multicentre, Pragmatic Trial of a Digital Medicine System
Corey Fowler, Otsuka Pharmaceuticals
Corey Fowler*, Nathan Cope, Jonathan Knights, Hui Fang, Taisa Skubiak, Peter Phiri, Shanaya Rathod, Timothy Peters-Strickland

69. The Effects of Anticholinergic Burden on Neurocognition in Schizophrenia for Individuals Treated With Clozapine
McKenzie Osborne, Manhattan Psychiatric Center
McKenzie Osborne*, Anzalee Khan, Jean-Pierre Lindenmayer, Beverly Insel, Abraham Goldring, Susan McGurk

70. Impact of Excessive Daytime Sleepiness on function and Productivity Among Participants With Major Depressive Disorder: A Qualitative Study
Andrew Krystal, UCSF
Andrew Krystal*, Leah Kleinman, Shannon Shaffer, Timothy Howell, Susan Morris, Kimberly Babson, Grace Wang, Ruth Benca

71. Palatability Assessment of a New Amphetamine Extended-Release Tablet Formulation
William Seidel, Tris Pharma
Antonio Pardo, Thomas King, William Seidel*, Judith Kando

72. A Combination Drug Candidate for Treatment of Substance Use Disorders
Tong Lee, Generys Biopharmaceuticals Corp.
Tong Lee*, Ashwin Patkar, Shein Chow, Steven Szabo, Dale Christensen, Ramana Kuchibhatla, Brett Froeliger, Kamal Bhatia

73. ADVANCE: Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Negative Symptoms of Schizophrenia
Dragana Bugarski-Kirola, ACADIA Pharmaceuticals Inc.
Dragana Bugarski-Kirola*, Celso Arango, Maurizio Fava, Henry Nasrallah, I-Yuan Liu, Brandon Abbs, Srdjan Stankovic

74. KarXT (A Combination of the Cholinergic Agonist Xanomeline With Trospium to Enhance Tolerability), is Superior to Placebo in Patients With Schizophrenia: Phase 2 Clinical Trial Results
Stephen Brannan, Karuna
Stephen Brannan*, Sharon Sawchak, Andrew Miller, Steven Paul, Alan Breier
75. SEP-363856: A Compound with a Non-D2 Receptor Mechanism of Action for the Treatment of Schizophrenia: Update
Kenneth Koblan, Sunovion Pharmaceuticals, Inc.
Kenneth Koblan*, Justine Kent

76. Psilocybin Therapy for Treatment-Resistant Depression: Results From a Phase 1, Double-Blind, Placebo-Controlled Trial With Exploratory Efficacy Measures
Hans Eriksson, COMPASS Pathways
Hans Eriksson*, James Rucker, Allan H Young, Catherine Bird, Lindsey Marwood, Francesco Saldarini, Susan Stansfield, Neil Weston, Sam Williams, Ekaterina Malievskaiia